Newbury Pharmaceuticals Q2: Initial Take - Redeye

Redeye leaves an initial comment following the Q2 report published by Newbury this morning. The company follows up last quarters strong sales figures with a more modest financial report. While net sales and EBIT came in below our estimates, the Q2 report will likely not cause any major adjustments to our long-term forecasts.

Länk till analysen i sin helhet: https://www.redeye.se/research/994917/newbury-pharmaceuticals-q2-initial-take-2?utm_source=finwire&utm_medium=RSS